BACTERIAL VAGINOSIS DRUGS MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: BYR-96729 | Health Care
Historical data: 2017 - 2023
Forecast period: 2025 - 2031
Quantitative units: Revenue in USD million and CAGR from 2025 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Bacterial Vaginosis Drugs Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET
7.1 GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE AND SHARE (2017 - 2031) (USD MILLION)
8.1 GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
8.2 GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
9.1 GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
9.2 GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
10.1 GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE AND SHARE BY REGION (2017 - 2023) (USD MILLION)
10.2 GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE AND SHARE BY REGION (2025 - 2031) (USD MILLION)
11.1 NORTH AMERICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
11.2 NORTH AMERICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
11.3 NORTH AMERICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
11.4 NORTH AMERICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
11.5 NORTH AMERICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
11.6 NORTH AMERICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
12.1 EUROPE BACTERIAL VAGINOSIS DRUGS MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
12.2 EUROPE BACTERIAL VAGINOSIS DRUGS MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
12.3 EUROPE BACTERIAL VAGINOSIS DRUGS MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
12.4 EUROPE BACTERIAL VAGINOSIS DRUGS MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
12.5 EUROPE BACTERIAL VAGINOSIS DRUGS MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
12.6 EUROPE BACTERIAL VAGINOSIS DRUGS MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
13.1 ASIA PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
13.2 ASIA PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
13.3 ASIA PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
13.4 ASIA PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
13.5 ASIA PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
13.6 ASIA PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
14.1 LATIN AMERICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)/p>
14.2 LATIN AMERICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
14.3 LATIN AMERICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
14.4 LATIN AMERICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
14.5 LATIN AMERICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
14.6 LATIN AMERICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031)< (USD MILLION)/p>
16.1 Bayer AG (Germany)
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 Pfizer Inc. (United States)
16.3 Sanofi S.A. (France)
16.4 The Piramal Group (India)
16.5 Abbott Laboratories (United States)
16.6 Galderma S.A. (Switzerland)
16.7 Alkem Laboratories (India)
16.8 Xiuzheng Pharmaceutical Co.Ltd. (China)
16.9 Teva Pharmaceuticals Industries Ltd. (Israel)
16.10 Perrigo PLC (Ireland)
16.11 Hikma (United States)
16.12 Harbin Pharmaceuticals Group Holding Co.Ltd.(India)
16.13 Yunnan Baiyao (China)
16.14 Starpharma Holdings (Australia)
16.15 Lupin Inc.(India)
16.16 Sun Pharmaceuticals Industries Ltd. (India)
16.17 Cardinal Health Inc. (United States)
16.18 Astrazeneca PLC (United KIngdom)
16.19 Mylan N.V (United States)
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
By TypeOral
Topical
By Application
Pelvic Inflammatory Disease
Preterm Delivery of Infants
Urinary Tract Infection
Sexually Transmitted Diseases (STD)
By Sales Channel
Direct Channel
Indirect Channel
By Topical Route
Metronidazole
Clindamycin
Retention Gels (Viva GelCanesbalance)
By End user
Hospitals
Drugs Stores
Others
By Oral Route
Metronidazole
Tinidazole
Clindamycin
By Mode of Drugs
Rx
OTC (Over the Counter)
Companies
Bayer AG (Germany)
Pfizer Inc. (United States)
Sanofi S.A. (France)
The Piramal Group (India)
Abbott Laboratories (United States)
Galderma S.A. (Switzerland)
Alkem Laboratories (India)
Xiuzheng Pharmaceutical Co.Ltd. (China)
Teva Pharmaceuticals Industries Ltd. (Israel)
Perrigo PLC (Ireland)
Hikma (United States)
Harbin Pharmaceuticals Group Holding Co.Ltd.(India)
Yunnan Baiyao (China)
Starpharma Holdings (Australia)
Lupin Inc.(India)
Sun Pharmaceuticals Industries Ltd. (India)
Cardinal Health Inc. (United States)
Astrazeneca PLC (United KIngdom)
Mylan N.V (United States)
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.